← Leaderboards
Kristy M Ainslie
Univ Of North Carolina Chapel Hill
$15,971,668
Attributed
$19,120,078
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,120,078 · 12
By mechanism
R01$16,615,917 · 7
R21$1,252,726 · 3
R33$974,217 · 1
R41$277,218 · 1
Top collaborators
- Bruce E Blough6 shared
- Anil Kumar Goyal1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Elizabeth Grace Gurysh$133,052
Others in their field
Top investigators on “Dextrans”
- Zaver M Bhujwalla · Johns Hopkins University$10,656,022
- Margie L. Clapper · Fox Chase Cancer Center$8,381,945
- Keith T Wilson · Vanderbilt University Medical Center$6,923,090
- Cristian Apetrei · University Of Pittsburgh At Pittsburgh$6,196,896
- Elisa E Konofagou · Columbia University Health Sciences$6,183,335
- Hyun Koo · University Of Pennsylvania$5,954,923
Research focus
DextransPolymersEncapsulatedDoseParticleCellsIn VitroIn VivoAcidsAffectPharmaceutical PreparationsImmuneDesignFormulationEvaluationAntigensInfectionMouse ModelPhagocytesResponseAnimal ModelMacrophageKineticsCessation Of Life
Grant awards (41)
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.$612,133
R01 · FY2025 · AI · contact PI
Biodegradable polymeric microparticles comprised of acetalated dextran induce immune tolerance$501,011
R01 · FY2025 · AI · contact PI
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma$349,391
R01 · FY2025 · CA · contact PI
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.$618,197
R01 · FY2024 · AI · contact PI
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine$553,436
R01 · FY2024 · AI · contact PI
Formulation to Generate Tolerance Towards Type 1 Diabetes$366,138
R01 · FY2024 · DK · contact PI
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma$332,114
R01 · FY2024 · CA · contact PI
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.$645,188
R01 · FY2023 · AI · contact PI
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine$560,411
R01 · FY2023 · AI · contact PI
Formulation to Generate Tolerance Towards Type 1 Diabetes$381,608
R01 · FY2023 · DK · contact PI
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma$342,991
R01 · FY2023 · CA · contact PI
Formulation to Generate Tolerance Towards Type 1 Diabetes$110,794
R01 · FY2023 · DK · contact PI
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine$568,652
R01 · FY2022 · AI · contact PI
Formulation to Generate Tolerance Towards Type 1 Diabetes$381,816
R01 · FY2022 · DK · contact PI
Biomaterials to study tolerance immune induction kinetics$376,558
R01 · FY2022 · AI · contact PI
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma$349,093
R01 · FY2022 · CA · contact PI
Diversity Supplement - Formulation to Generate Tolerance Towards Type 1 Diabetes$110,072
R01 · FY2022 · DK · contact PI
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine$578,536
R01 · FY2021 · AI · contact PI
Formulation to Generate Tolerance Towards Type 1 Diabetes$382,018
R01 · FY2021 · DK · contact PI
Biomaterials to study tolerance immune induction kinetics$376,558
R01 · FY2021 · AI · contact PI
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma$356,423
R01 · FY2021 · CA · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,043,412
R01 · FY2020 · AI · contact PI
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine$604,292
R01 · FY2020 · AI · contact PI
Biomaterials to study tolerance immune induction kinetics$376,558
R01 · FY2020 · AI · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,092,009
R01 · FY2019 · AI · contact PI
Biomaterials to study tolerance immune induction kinetics$376,558
R01 · FY2019 · AI · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,159,484
R01 · FY2018 · AI · contact PI
Biomaterials to study tolerance immune induction kinetics$385,768
R01 · FY2018 · AI · contact PI
Advancing Formulation of STING agonist for Universal Flu Vaccine$277,218
R41 · FY2018 · AI · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,279,158
R01 · FY2017 · AI · contact PI
Microparticle resiquimod for the treatment of visceral leishmaniasis$224,481
R21 · FY2017 · AI · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$1,406,823
R01 · FY2016 · AI · contact PI
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens$351,320
R33 · FY2016 · AI · contact PI
Microparticle resiquimod for the treatment of visceral leishmaniasis$199,258
R21 · FY2016 · AI · contact PI
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection$38,717
R01 · FY2016 · AI · contact PI
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens$315,308
R33 · FY2015 · AI · contact PI
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens$307,589
R33 · FY2014 · AI · contact PI
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens$221,838
R21 · FY2013 · AI · contact PI
Encapsulated Active Vitamin D Vaccine for the Treatment of Multiple Sclerosis$190,625
R21 · FY2012 · NS · contact PI
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens$187,774
R21 · FY2012 · AI · contact PI
Encapsulated Active Vitamin D Vaccine for the Treatment of Multiple Sclerosis$228,750
R21 · FY2011 · NS · contact PI